Ovesterin (Estriol)

Estriol, the active ingredient in Ovesterin, is an estrogen presented as a vaginal formulation for vaginal use. It helps restore normal vaginal physiology by promoting epithelial proliferation, relieving dryness, itching, and dyspareunia in postmenopausal women, thereby improving quality of life. The formulation is designed for local delivery, minimizing systemic exposure while providing effective symptom relief.

GNH USA supplies Ovesterin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Estriol is used in hormone replacement therapy to address conditions affecting the vaginal tissue. - Vaginal atrophy: restores thinning vaginal epithelium and reduces dryness. - Dyspareunia associated with menopause: alleviates pain during intercourse by improving lubrication. - Menopausal genitourinary syndrome: improves overall genital tract health and reduces urinary symptoms.

Estriol may cause a range of local and systemic adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Vaginal irritation: mild burning or stinging sensation. - Discharge: increased vaginal secretions. - Itching: localized pruritus. - Headache: mild tension-type headache. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Allergic reaction: rash, swelling, or anaphylaxis. - Endometrial hyperplasia: abnormal uterine bleeding. - Vaginal bleeding: unexpected spotting. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Breast tenderness: persistent pain or enlargement.

Before prescribing Estriol, clinicians should evaluate patient history and follow safety guidelines to minimize risks. - Assess contraindications: history of estrogen‑dependent neoplasia or thromboembolic disease. - Review medical history: liver dysfunction, cardiovascular disease, or uncontrolled hypertension. - Monitor symptoms: report unusual vaginal bleeding or breast changes promptly. - Consider drug interactions: avoid concomitant use with potent estrogen therapies without supervision. - Evaluate pregnancy status: avoid use in women who are pregnant or may become pregnant. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Estriol can interact with other medicines, altering its efficacy or increasing adverse effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Hormonal contraceptives: additive estrogen effect may raise thrombotic risk. - Tamoxifen or aromatase inhibitors: reduced therapeutic benefit in estrogen‑dependent conditions.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood pressure control. - Thyroid hormones: may affect thyroid‑binding globulin levels. - Antidepressants (SSRIs): potential for altered metabolism via CYP enzymes.